- Summer Drinking Poses Unique And Sobering Risks
- FDA Approves Juul E-Cigs for Sale, Years After Ban Attempt
- 8 Babies Born Using New IVF Technique to Prevent Rare Genetic Diseases
- Trump Diagnosed With Common Vein Condition in the Legs
- Hispanic People Have Unexplained Higher Risk For Nerve Disorder
- Diabetic Women Should Be Asked About Desire For Kids At Every Doctor’s Visit, Guidelines Say
- Nieces, Nephews Become Dementia Caregivers Unexpectedly, Study Says
- Depression Risk Greater In Some Women With Premature Menopause
- What Are The Best Treatments For Chronic Hives?
- Poor Oral Health Potentially Linked To Chronic Health Problems
Extended-Release Hydrocodone Painkiller Approved

FRIDAY, Oct. 25Zohydro ER (hydrocodone bitartrate extended-release) has been approved by the U.S. Food and Drug Administration for severe pain that requires round-the-clock long-term treatment, the agency said Friday in a news release.
Citing the potential for opioid abuse or dependency, even if the product is used as prescribed, the agency said the drug should be used only in cases when other painkillers have proven ineffective. The schedule II controlled substance should only be used to treat daily, chronic pain, not for as-needed pain relief, the FDA said.
The agency said it has ordered post-marketing studies of Zohydro ER to evaluate use beyond 12 weeks, and its overall potential for abuse.
The drug was evaluated in clinical studies involving more than 1,100 people with chronic pain. The most common side effects included constipation, nausea, drowsiness, headache, dizziness, dry mouth and itching.
Zohydro ER is produced by Zogenix, based in San Diego.
More information
To learn more about chronic pain, visit the U.S. National Institute of Neurological Disorders and Stroke.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.